F(ab')2 fragments of anti-Mo1 (904) monoclonal antibodies do not prevent myocardial stunning.

Display options

Format

Share it on

Full text links

Circ Res. 1989 Oct;65(4):1112-24. doi: 10.1161/01.res.65.4.1112.

F(ab')2 fragments of anti-Mo1 (904) monoclonal antibodies do not prevent myocardial stunning.

Circulation research

R J Schott, B S Nao, T B McClanahan, P J Simpson, M C Stirling, R F Todd, K P Gallagher

Affiliations

Department of Surgery, University of Michigan Medical School, Ann Arbor.

PMID: 2551527 DOI: 10.1161/01.res.65.4.1112

Abstract

To determine if inhibition of leukocyte adhesion and aggregation could improve postischemic ventricular dysfunction ("stunning"), a monoclonal antibody (904) that binds to the adhesion-promoting Mo1 glycoprotein on the cell surface of leukocytes was administered intravenously (0.5 mg/kg) to open-chest dogs before a 15-minute coronary occlusion. Ultrasonic crystals placed in ischemic and control myocardium were used to measure systolic wall thickening during a 15-minute occlusion of the left anterior descending artery and for 3 hours after reperfusion. Myocardial blood flow was measured with tracer-labeled microspheres before occlusion, after 10 minutes of occlusion, 3 minutes of reperfusion, and at 1 and 3 hours after reperfusion. Six animals receiving anti-Mo1 antibody had antibody excess demonstrated with immunofluorescence techniques at 5 minutes and 3 hours of reperfusion; this finding indicated saturation of binding sites. Five animals served as controls and received an antibody (murine immunoglobulin G) that does not influence neutrophils. The two groups did not differ hemodynamically during ischemia and reperfusion. Risk areas and myocardial blood flow were also not significantly different between the two groups. The main parameter used to define regional myocardial stunning, percentage systolic wall thickening in the ischemic/reperfused area, did not differ significantly between the two groups. Specimens from nonischemic myocardium were compared with ischemic specimens for myeloperoxidase content. There were no significant differences within or between groups. These data indicate that the anti-Mo1 monoclonal antibody (904) is not effective in improving the profound myocardial dysfunction that persists for 3 hours of reperfusion after 15 minutes of ischemia.

F(ab')2 fragments of anti-Mo1 (904) monoclonal antibodies do not prevent myocardial stunning.

Affiliations

Abstract

Similar articles

Substances

MeSH terms

Publication Types

Grant support

LinkOut - more resources